

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

30th September 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani
MAIL :	info@chordiatherapeutics.com

Announcement Regarding AMED Grant Award for rogocekib (CTX-712)

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) is pleased to announce that its research and development project related to rogocekib (development code: CTX-712), currently under development by Chordia, has been selected under the FY2026 Advanced Research and Development Programs for Medical Innovation (Industry-Academia-Government Collaboration Type), Global-Type Program for Global Research and Development of Treatments for Intractable and Rare Diseases (the “Program”), publicly solicited by the Japan Agency for Medical Research and Development (“AMED”).

Chordia believes that this selection reflects AMED's high evaluation of rogocekib's novel mechanism of action involving modulation of RNA splicing and the innovative and socially significant nature of its global development strategy. In addition, through this selection, Chordia expects to receive competitive funding support of up to JPY 1.5 billion, which is expected to further accelerate the global development of rogocekib.

Research and Development Project Title:

A Phase I/II Study of CTX-712 (rogocekib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Grant Amount: Up to JPY 1.5 billion

- The grant will cover up to one-half of eligible project expenses.
- The actual amount awarded will be determined based on future research and development plans.
- Project period: October 1, 2026 through November 30, 2029. (Scheduled)

1. Background and Objectives of the Research and Development Project

Acute myeloid leukemia ("AML") is a rapidly progressing disease, and patients with relapsed or refractory AML continue to have a poor prognosis. As a result, there remains a strong need for the development of new therapeutic options. In particular, for patients whose disease has relapsed following, or become resistant to, recently introduced therapies, there is no sufficiently established standard treatment, resulting in a significant unmet medical need.

Rogocekib is a novel orally available small-molecule compound that inhibits CDC-like kinase (CLK), a key regulator of RNA splicing. Through this novel mechanism of action, rogocekib is expected to demonstrate selective anti-tumor activity against cancer cells. Clinical studies conducted to date have generated results suggesting potential efficacy in patients with relapsed or refractory AML and high-risk myelodysplastic syndromes ("HR-MDS").

Chordia is currently conducting a Phase I/II clinical trial of rogocekib in the United States and is advancing its development as an international joint clinical trial that will also include Japan. Rogocekib has received Orphan Drug Designation for AML from the U.S. Food and Drug Administration (FDA) and has also been designated as an orphan drug by the Ministry of Health, Labour and Welfare in Japan.

Through this Program, Chordia will further evaluate the safety and efficacy of rogocekib in patients with relapsed or refractory AML and HR-MDS through an international joint clinical trial. By leveraging funding provided under this Program, Chordia aims to accelerate the development of rogocekib and deliver a new treatment option to patients in need.

2. Outlook

The impact of this Program on Chordia's financial results is currently undetermined, as details including the amount of the grant to be awarded have not yet been finalized. Chordia will promptly disclose any material developments as required.